Table 2. Univariate and multivariate analyses of patient characteristics and treatments associated with EFS.
| Characteristics |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Melphalan dose, mg/m2 | 0.044 | 0.268 | ||
| 100 | 2.1 (1.1–3.7) | 1.4 (0.6–3.2) | ||
| 140 | 1.2 (0.7–1.8) | 0.8 (0.41–1.5) | ||
| 200 | 1.0 | 1.0 | ||
| Age at SCT, years | 1.01 (0.9–1.03) | 0.333 | ||
| Induction of chemotherapy | 0.004 | 0.128 | ||
| Yes | 1.9 (1.2–3.0) | 1.8 (0.8–4.1) | ||
| No | 1.0 | 1.0 | ||
| No. organs involved, n | <0.001 | 0.756 | ||
| 1 | 1.0 | 1.0 | ||
| 2/3/4/5 | 1.8 (1.2–2.6) | 1.1 (0.6–2.0) | ||
| Cardiac stage | 0.036 | 0.129 | ||
| I | 1.0 | 1.0 | ||
| II | 1.8 (0.9–3.1) | 1.7 (0.8–3.5) | ||
| III | 2.6 (1.2–5.5) | 2.5 (1.02–6.1) | ||
| Baseline 24 h creatinine clearance, ml/min | 0.778 | |||
| ⩾50 | 1.0 | |||
| <50 | 0.9 (0.5–1.5) | |||
| Baseline plasma cell | 0.501 | |||
| >10% | 1.2 (0.8–1.7) | |||
| ⩽10% | 1.0 | |||
| Protocols | 0.316 | |||
| 02–031 | 0.9 (0.5–1.4) | |||
| 07–006 | 0.7 (0.4–1.2) | |||
| Off study | 1.0 | |||
Abbreviations: CI, confidence interval; EFS, event-free survival; HR, hazard ratio; SCT, stem cell transplantation.